Trial Profile
A Phase I/IB Intergroup Trial of the HU14.18-IL2 Fusion Protein in Children With Refractory Neuroblastoma and Other GD2 Positive Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lorukafusp alfa (Primary)
- Indications Malignant melanoma; Neuroblastoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- 01 Oct 2005 New trial record.